Freenome's SimpleScreen CRC gains FDA approval; $100M Abbott milestone, Medicare ...

Freenome's SimpleScreen CRC blood-based colorectal cancer screening test gained FDA approval for average-risk adults 45+, with 81.1% sensitivity for CRC and expected Medicare coverage. Abbott will exclusively commercialise the test in the US and paid a $100 million milestone, with Freenome planning to integrate it into its broader cancer screening portfolio.

This Wire brief sits within Fusion42's coverage of Diagnostics. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.